GenMark Diagnostics, Inc. (GNMK): Price and Financial Metrics


GenMark Diagnostics, Inc. (GNMK): $18.95

0.01 (+0.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GNMK Stock Summary

  • The price/operating cash flow metric for GenMark Diagnostics Inc is higher than 97.72% of stocks in our set with a positive cash flow.
  • GNMK's price/sales ratio is 8.07; that's higher than the P/S ratio of 78.62% of US stocks.
  • Revenue growth over the past 12 months for GenMark Diagnostics Inc comes in at 94.9%, a number that bests 94.34% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GenMark Diagnostics Inc are RDFN, TRXC, DYAI, GKOS, and PSTG.
  • Visit GNMK's SEC page to see the company's official filings. To visit the company's web site, go to www.genmarkdx.com.

GNMK Stock Price Chart Interactive Chart >

Price chart for GNMK

GNMK Price/Volume Stats

Current price $18.95 52-week high $23.59
Prev. close $18.94 52-week low $3.37
Day low $18.50 Volume 508,708
Day high $19.34 Avg. volume 1,251,316
50-day MA $16.44 Dividend yield N/A
200-day MA $14.30 Market Cap 1.38B

GenMark Diagnostics, Inc. (GNMK) Company Bio


GenMark Diagnostics, Inc. develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company is based in Carlsbad, California.


GNMK Latest News Stream


Event/Time News Detail
Loading, please wait...

GNMK Latest Social Stream


Loading social stream, please wait...

View Full GNMK Social Stream

Latest GNMK News From Around the Web

Below are the latest news stories about GenMark Diagnostics Inc that investors may wish to consider to help them evaluate GNMK as an investment opportunity.

GenMark Diagnostics, Inc. (GNMK) CEO Scott Mendel on Q4 2020 Results - Earnings Call Transcript

GenMark Diagnostics, Inc. (GNMK) Q4 2020 Earnings Conference Call February 25, 2021 04:30 PM ET Company Participants Leigh Salvo - Investor Relations, Gilmartin Group LLC Scott Mendel - President & Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants Chris Shibutani - Cowen Stephanie Yan - Canaccord...

SA Transcripts on Seeking Alpha | February 26, 2021

Canaccord Genuity Stick to Their Buy Rating for Genmark Diagnostics By Investing.com

Canaccord Genuity Stick to Their Buy Rating for Genmark Diagnostics

Investing.com | February 25, 2021

GenMark Diagnostics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis

GenMark Diagnostics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | February 24, 2021

GenMark ePlex® RP2 Panel Predicted to Detect Known SARS-CoV-2 Variants Currently in Circulation Based on in silico Analysis

CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS-CoV-2 variants currently in circulation. As the COVID-19 pandemic continues to evolve, GenMark is routinely monitoring publicly available databases for new SARS-CoV-2 strains and variants and conducting bioinformatic analyses to determine if the mutations present in the viral genome would impact detection of these variants on the ePlex RP2 Panel. The recently identified SARS-CoV-2 variant strains include multiple mutations with the majority occurring in the spike protein, or S gene region and additional mutations fou...

Yahoo | February 22, 2021

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference. GenMark’s management team is scheduled to present in a virtual setting on Monday, March 1st, 2021 at 2:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com ABOUT GENMARKGenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark’s proprietary eSensor® detection technology, GenMark’s e...

Yahoo | February 16, 2021

Read More 'GNMK' Stories Here

GNMK Price Returns

1-mo 38.62%
3-mo 37.42%
6-mo 64.93%
1-year 342.76%
3-year 343.79%
5-year 226.16%
YTD 29.79%
2020 203.53%
2019 -1.03%
2018 16.55%
2017 -65.93%
2016 57.73%

Continue Researching GNMK

Want to see what other sources are saying about GenMark Diagnostics Inc's financials and stock price? Try the links below:

GenMark Diagnostics Inc (GNMK) Stock Price | Nasdaq
GenMark Diagnostics Inc (GNMK) Stock Quote, History and News - Yahoo Finance
GenMark Diagnostics Inc (GNMK) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8953 seconds.